K H Lo1, J Donohue2, M A Judson3, Y Wu1, E S Barnathan1, R P Baughman4. 1. Janssen Research and Development, LLC, Raritan, USA. 2. The University of North Carolina, Chapel Hill, NC, USA. 3. Albany Medical Center, Albany, NY, USA. 4. The University of Cincinnati Medical Center, 200 Albert Sabin Way, Cincinnati, OH, 45267, USA. bob.baughman@uc.edu.
Abstract
RATIONALE: The Saint George's Respiratory Questionnaire (SGRQ) is a frequently used tool to assess health status in pulmonary disease patients. However, its performance characteristics in sarcoidosis patients are not well characterized. METHODS: Data from a clinical trial of 138 symptomatic adults with sarcoidosis were used to examine the performance characteristics of SGRQ. Data were available at both baseline and week 24. Other assessments included FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6-min walk distance (6MWD), and Short Form-36 Physical Component Summary (SF-36 PCS) score. RESULTS: Baseline SGRQ was 46.8, indicating impaired health status. At baseline, SGRQ total score correlated significantly with % predicted FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6MWD, and SF-36 PCS (r = - 0.37, - 0.32, 0.57, 0.40, - 0.55, and - 0.80, respectively, p < 0.001). Change from baseline in SGRQ score also statistically significantly correlated with change from baseline in these parameters at week 24: r = - 0.25, - 0.20, 0.30, 0.22, - 0.20, - 0.45, respectively (p < 0.05). CONCLUSIONS: The SGRQ correlated with other outcome measures in sarcoidosis initially and with treatment. Improvement in FVC % predicted correlated with improvement in SGRQ. These data suggest the SGRQ may function as a reliable endpoint in clinical sarcoidosis trials.
RATIONALE: The Saint George's Respiratory Questionnaire (SGRQ) is a frequently used tool to assess health status in pulmonary diseasepatients. However, its performance characteristics in sarcoidosispatients are not well characterized. METHODS: Data from a clinical trial of 138 symptomatic adults with sarcoidosis were used to examine the performance characteristics of SGRQ. Data were available at both baseline and week 24. Other assessments included FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6-min walk distance (6MWD), and Short Form-36 Physical Component Summary (SF-36 PCS) score. RESULTS: Baseline SGRQ was 46.8, indicating impaired health status. At baseline, SGRQ total score correlated significantly with % predicted FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6MWD, and SF-36 PCS (r = - 0.37, - 0.32, 0.57, 0.40, - 0.55, and - 0.80, respectively, p < 0.001). Change from baseline in SGRQ score also statistically significantly correlated with change from baseline in these parameters at week 24: r = - 0.25, - 0.20, 0.30, 0.22, - 0.20, - 0.45, respectively (p < 0.05). CONCLUSIONS: The SGRQ correlated with other outcome measures in sarcoidosis initially and with treatment. Improvement in FVC % predicted correlated with improvement in SGRQ. These data suggest the SGRQ may function as a reliable endpoint in clinical sarcoidosis trials.
Entities:
Keywords:
Quality of life; SF-36; SGRQ; Sarcoidosis; Short form 36
Authors: M A Judson; K B Highland; S Kwon; J F Donohue; R Aris; N Craft; S Burt; H J Ford Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2011-10 Impact factor: 0.670
Authors: R P Baughman; M A Judson; E E Lower; K Highland; S Kwon; N Craft; P J Engel Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2009-07 Impact factor: 0.670
Authors: R P Baughman; M Drent; D A Culver; J C Grutters; T Handa; M Humbert; M A Judson; E E Lower; J Mana; C A Pereira; A Prasse; R Sulica; D Valyere; V Vucinic; A U Wells Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2012-10 Impact factor: 0.670
Authors: Marcia A Friedman; Brian Le; Janelle Stevens; Julianna Desmarais; Daniel Seifer; Kimberly Ogle; Dongseok Choi; Christina A Harrington; Peter Jackson; James T Rosenbaum Journal: Lung Date: 2021-04-07 Impact factor: 2.584
Authors: Brooke M Currie; Evan W Davies; Amélie Beaudet; Larissa Stassek; Leah Kleinman; Robert P Baughman Journal: BMC Pulm Med Date: 2021-11-12 Impact factor: 3.317
Authors: Robert P Baughman; Oksana A Shlobin; Rohit Gupta; Peter J Engel; Jeffrey I Stewart; Elyse E Lower; Franck F Rahaghi; Joyce Zeigler; Steven D Nathan Journal: Chest Date: 2021-08-04 Impact factor: 9.410